Literature DB >> 27518777

Immune Modulation and Prevention of Autoimmune Disease by Repeated Sequences from Parasites Linked to Self Antigens.

Fabiola Puentes1,2, Katharina Dickhaut3, Maria Hofstätter3, Jennifer Pfeil4, Uta Lauer4, Alf Hamann4, Ute Hoffmann4, Kirsten Falk3, Olaf Rötzschke3,5.   

Abstract

Parasite proteins containing repeats are essential invasion ligands, important for their ability to evade the host immune system and to induce immunosuppression. Here, the intrinsic suppressive potential of repetitive structures within parasite proteins was exploited to induce immunomodulation in order to establish self-tolerance in an animal model of autoimmune neurological disease. We tested the tolerogenic potential of fusion proteins containing repeat sequences of parasites linked to self-antigens. The fusion constructs consist of a recombinant protein containing repeat sequences derived from the S-antigen protein (SAg) of Plasmodium falciparum linked to a CD4 T cell epitope of myelin. They were tested for their efficacy to control the development of experimental autoimmune encephalomyelitis (EAE), In addition, we used the DO11.10 transgenic mouse model to study the immune mechanisms involved in tolerance induced by SAg fusion proteins. We found that repeated sequences of P. falciparum SAg protein linked to self-epitopes markedly protected mice from EAE. These fusion constructs were powerful tolerizing agents not only in a preventive setting but also in the treatment of ongoing disease. The tolerogenic effect was shown to be antigen-specific and strongly dependent on the physical linkage of the T cell epitope to the parasite structure and on the action of anti-inflammatory cytokines like IL-10 and TGF-β. Other mechanisms include down-regulation of TNF-α accompanied by increased numbers of FoxP3+ cells. This study describes the use of repetitive structures from parasites linked to defined T cell epitopes as an effective method to induce antigen-specific tolerance with potential applicability for the treatment and prevention of autoimmune diseases.

Entities:  

Keywords:  EAE; Immunomodulation; Multiple sclerosis; Repetitive antigens; Self-antigens

Mesh:

Substances:

Year:  2016        PMID: 27518777     DOI: 10.1007/s11481-016-9701-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  68 in total

1.  Immunology of malaria infections.

Authors:  M M Stevenson; F Zavala
Journal:  Parasite Immunol       Date:  2006 Jan-Feb       Impact factor: 2.280

2.  Anomalous behaviour of a protein during SDS/PAGE corrected by chemical modification of carboxylic groups.

Authors:  A Matagne; B Joris; J M Frère
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

3.  Parasite-mediated down-regulation of collagen-induced arthritis (CIA) in DA rats.

Authors:  L Mattsson; P Larsson; H Erlandsson-Harris; L Klareskog; R A Harris
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 4.  Induction of antigen-specific tolerance through hematopoietic stem cell-mediated gene therapy: the future for therapy of autoimmune disease?

Authors:  Miranda A Coleman; Raymond J Steptoe
Journal:  Autoimmun Rev       Date:  2012-10-06       Impact factor: 9.754

Review 5.  Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis.

Authors:  Danielle M Turley; Stephen D Miller
Journal:  Results Probl Cell Differ       Date:  2010

Review 6.  Virulence and the immune response in malaria.

Authors:  G A Targett
Journal:  Mem Inst Oswaldo Cruz       Date:  1992       Impact factor: 2.743

Review 7.  Autoimmunity and apoptosis--therapeutic implications.

Authors:  Iran Rashedi; Soumya Panigrahi; Peyman Ezzati; Saeid Ghavami; Marek Los
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

8.  Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses.

Authors:  Kevin P Walsh; Miriam T Brady; Conor M Finlay; Louis Boon; Kingston H G Mills
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

9.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  5 in total

Review 1.  Advances in Autoimmune Epilepsy Associated with Antibodies, Their Potential Pathogenic Molecular Mechanisms, and Current Recommended Immunotherapies.

Authors:  Zhiwei Fang; Yunqi Yang; Xuan Chen; Weiwang Zhang; Yangmei Xie; Yinghui Chen; Zhenguo Liu; Weien Yuan
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

2.  Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.

Authors:  Jennifer Pfeil; Mario Simonetti; Uta Lauer; Bianca von Thülen; Pawel Durek; Christina Poulsen; Justyna Pawlowska; Matthias Kröger; Ralf Krähmer; Frank Leenders; Ute Hoffmann; Alf Hamann
Journal:  Ther Adv Chronic Dis       Date:  2021-08-12       Impact factor: 5.091

Review 3.  Malaria Parasites: The Great Escape.

Authors:  Laurent Rénia; Yun Shan Goh
Journal:  Front Immunol       Date:  2016-11-07       Impact factor: 7.561

4.  Tolerogenic Immunomodulation by PEGylated Antigenic Peptides.

Authors:  Jennifer Pfeil; Mario Simonetti; Uta Lauer; Rudolf Volkmer; Bianca von Thülen; Pawel Durek; Ralf Krähmer; Frank Leenders; Alf Hamann; Ute Hoffmann
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 5.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.